Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash from Financing Activities (2022 - 2025)

Coya Therapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at $19137.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 133.97% year-over-year to $19137.0; the TTM value through Sep 2025 reached $9.7 million, down 68.11%, while the annual FY2024 figure was $16.0 million, 58.29% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $19137.0 at Coya Therapeutics, roughly flat from $19137.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $24.2 million in Q4 2023 and bottomed at -$104071.0 in Q4 2022.
  • The 4-year median for Cash from Financing Activities is $630450.5 (2024), against an average of $5.3 million.
  • The largest annual shift saw Cash from Financing Activities soared 23329.1% in 2023 before it plummeted 98.46% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at -$104071.0 in 2022, then skyrocketed by 23329.1% to $24.2 million in 2023, then tumbled by 59.91% to $9.7 million in 2024, then tumbled by 99.8% to $19137.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Cash from Financing Activities are $19137.0 (Q3 2025), $19137.0 (Q1 2025), and $9.7 million (Q4 2024).